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BACKGROUND
Nivolumab plus ipilimumab produced objective responses in patients with advanced 
renal-cell carcinoma in a pilot study. This phase 3 trial compared nivolumab plus ipili-
mumab with sunitinib for previously untreated clear-cell advanced renal-cell carcinoma.
METHODS
We randomly assigned adults in a 1:1 ratio to receive either nivolumab (3 mg per 
kilogram of body weight) plus ipilimumab (1 mg per kilogram) intravenously every 
3 weeks for four doses, followed by nivolumab (3 mg per kilogram) every 2 weeks, 
or sunitinib (50 mg) orally once daily for 4 weeks (6-week cycle). The coprimary end 
points were overall survival (alpha level, 0.04), objective response rate (alpha level, 
0.001), and progression-free survival (alpha level, 0.009) among patients with inter-
mediate or poor prognostic risk.
RESULTS
A total of 1096 patients were assigned to receive nivolumab plus ipilimumab (550 
patients) or sunitinib (546 patients); 425 and 422, respectively, had intermediate or 
poor risk. At a median follow-up of 25.2 months in intermediate- and poor-risk pa-
tients, the 18-month overall survival rate was 75% (95% confidence interval [CI], 70 
to 78) with nivolumab plus ipilimumab and 60% (95% CI, 55 to 65) with sunitinib; 
the median overall survival was not reached with nivolumab plus ipilimumab versus 
26.0 months with sunitinib (hazard ratio for death, 0.63; P<0.001). The objective re-
sponse rate was 42% versus 27% (P<0.001), and the complete response rate was 9% 
versus 1%. The median progression-free survival was 11.6 months and 8.4 months, 
respectively (hazard ratio for disease progression or death, 0.82; P = 0.03, not signifi-
cant per the prespecified 0.009 threshold). Treatment-related adverse events occurred 
in 509 of 547 patients (93%) in the nivolumab-plus-ipilimumab group and 521 of 535 
patients (97%) in the sunitinib group; grade 3 or 4 events occurred in 250 patients 
(46%) and 335 patients (63%), respectively. Treatment-related adverse events leading 
to discontinuation occurred in 22% and 12% of the patients in the respective groups.
CONCLUSIONS
Overall survival and objective response rates were significantly higher with nivolumab 
plus ipilimumab than with sunitinib among intermediate- and poor-risk patients with 
previously untreated advanced renal-cell carcinoma. (Funded by Bristol-Myers Squibb 
and Ono Pharmaceutical; CheckMate 214 ClinicalTrials.gov number, NCT02231749.)
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Sunitinib, a vascular endothelial growth factor receptor tyrosine kinase in-hibitor, is a standard of care for first-line 
treatment of advanced renal-cell carcinoma.1 In 
a large, randomized, phase 3 trial involving pre-
viously untreated patients, the median progres-
sion-free survival with sunitinib was 9.5 months, 
the objective response rate was 25%, and the me-
dian overall survival was 29.3 months, with a high 
rate of hematologic toxic effects.2
The prognosis of patients with advanced re-
nal-cell carcinoma can be categorized according 
to favorable-, intermediate-, or poor-risk disease 
depending on the presence of well-characterized 
clinical and laboratory risk factors.3 A commonly 
used, validated model to assess prognosis was 
developed by the International Metastatic Renal 
Cell Carcinoma Database Consortium (IMDC).4,5 
Approximately 75% of patients with advanced 
renal-cell carcinoma have intermediate- or poor-
risk disease and have worse outcomes than those 
with favorable-risk disease.4,5
Nivolumab, a programmed death 1 (PD-1) 
immune checkpoint inhibitor antibody,6 is ap-
proved for the treatment of advanced renal-cell 
carcinoma after treatment with antiangiogenic 
therapy, on the basis of an overall survival ben-
efit.7 Ipilimumab, an anti–cytotoxic T-lympho-
cyte–associated antigen 4 antibody, is approved 
for the treatment of metastatic melanoma.8 
Although ipilimumab at a dose of 3 mg per 
kilogram of body weight was associated in one 
trial with an objective response rate of 13% 
among patients with metastatic renal-cell car-
cinoma, its toxic effects precluded further de-
velopment as monotherapy for this disease.9 
Combination therapy with nivolumab plus ipi-
lim umab has shown promising efficacy in 
multiple tumor types, resulting in higher rates 
of response than either agent alone,10-14 and is 
approved for the treatment of advanced mela-
noma.7 The combination has shown antitumor 
activity in previously untreated and previously 
treated patients with advanced renal-cell carci-
noma, with an objective response rate of 40% 
and a 2-year overall survival rate of 67 to 70%, 
depending on the dose.11 Here, we report re-
sults from the phase 3 CheckMate 214 trial of 
nivolumab plus ipilimumab versus sunitinib in 
previously untreated advanced renal-cell car-
cinoma.
Me thods
Patients
Eligible patients were 18 years of age or older, 
with previously untreated advanced renal-cell car-
cinoma with a clear-cell component. Additional 
key inclusion criteria were measurable disease 
according to the Response Evaluation Criteria in 
Solid Tumors (RECIST), version 1.1,15 and a Kar-
nofsky performance-status score of at least 70 
(on a scale from 0 to 100, with lower scores in-
dicating greater disability).16 Key exclusion criteria 
were central nervous system metastases or auto-
immune disease and glucocorticoid or immuno-
suppressant use. Patients were characterized ac-
cording to IMDC risk (favorable [score of 0], 
intermediate [score of 1 or 2], or poor [score of 
3 to 6]), defined according to the number of the 
following risk factors present: a Karnofsky per-
formance-status score of 70, a time from initial 
diagnosis to randomization of less than 1 year, 
a hemoglobin level below the lower limit of the 
normal range, a corrected serum calcium concen-
tration of more than 10 mg per deciliter (2.5 mmol 
per liter), an absolute neutrophil count above the 
upper limit of the normal range, and a platelet 
count above the upper limit of the normal range.4
Trial Design
This was a randomized, open-label, phase 3 trial 
of nivolumab plus ipilimumab followed by 
nivolumab monotherapy versus sunitinib mono-
therapy. Randomization (in a 1:1 ratio) was 
performed with a block size of 4 with stratifica-
tion according to IMDC risk score (0 vs. 1 or 2 vs. 
3 to 6) and geographic region (United States vs. 
Canada and Europe vs. the rest of the world).
Nivolumab and ipilimumab were administered 
intravenously at a dose of 3 mg per kilogram over 
a period of 60 minutes and 1 mg per kilogram 
over a period of 30 minutes, respectively, every 
3 weeks for four doses (induction phase), followed 
by nivolumab monotherapy at a dose of 3 mg per 
kilogram every 2 weeks (maintenance phase). 
Sunitinib was administered at a dose of 50 mg 
orally once daily for 4 weeks of each 6-week cycle. 
No dose reductions were allowed for nivolumab 
or ipilimumab. Dose delays for adverse events 
were permitted in both groups. Patients treated 
with nivolumab plus ipilimumab had to discon-
tinue both nivolumab and ipilimumab if they 
A Quick Take is 
available at 
NEJM.org 
n engl j med 378;14 nejm.org April 5, 2018 1279
Nivolumab plus Ipilimumab in Renal-Cell Carcinoma
had a treatment-related adverse event during the 
induction phase that required discontinuation, and 
they could not continue on to nivolumab mainte-
nance therapy. Detailed discontinuation criteria are 
shown in the Supplementary Appendix, available 
with the full text of this article at NEJM.org.
A November 2017 protocol amendment, after 
the primary end point had been met, permitted 
crossover from the sunitinib group to the 
nivolumab-plus-ipilimumab group. Nivolumab, 
ipilimumab, and sunitinib were provided by the 
sponsors, except when sunitinib was procured as 
a local commercial product in certain countries.
Trial Oversight
This trial was approved by the institutional review 
board or ethics committee at each site and was 
conducted according to Good Clinical Practice 
guidelines, defined by the International Confer-
ence on Harmonisation. All the patients provid-
ed written informed consent that was based on 
the Declaration of Helsinki principles. A data and 
safety monitoring committee reviewed efficacy 
and safety. The trial was designed by the authors 
in collaboration with the sponsors (Bristol-Myers 
Squibb and Ono Pharmaceutical). Bristol-Myers 
Squibb collected and analyzed the data with the 
authors. A data confidentiality agreement was in 
place between Bristol-Myers Squibb and the inves-
tigators. The authors vouch for the completeness 
and accuracy of the data and analyses and for 
the adherence of the trial to the protocol (avail-
able at NEJM.org). The development of the first 
draft of the manuscript was led by the first au-
thor and the last three authors; all the authors 
contributed to drafting the manuscript and pro-
vided final approval to submit the manuscript 
for publication. Medical writing support, funded 
by Bristol-Myers Squibb, was provided by PPSI.
End Points and Assessments
The coprimary end points were the objective re-
sponse rate, progression-free survival, and overall 
survival among intermediate- and poor-risk pa-
tients. The objective response rate was defined 
as the percentage of patients having a confirmed 
best response of complete response or partial re-
sponse according to RECIST, version 1.1, on the 
basis of assessment by an independent radiology 
review committee. Progression-free survival was 
defined as the time from randomization to first 
RECIST-defined progression or death. Overall sur-
vival was defined as the time from randomization 
to death.
Secondary end points included the objective 
response rate, progression-free survival, and over-
all survival, all in the intention-to-treat popula-
tion; and the incidence rate of adverse events 
among all treated patients. Exploratory end points 
included the objective response rate, progression-
free survival, and overall survival, all among fa-
vorable-risk patients. Additional exploratory end 
points included outcomes according to the level 
of tumor programmed death ligand 1 (PD-L1) ex-
pression (≥1% vs. <1%), as assessed at a central 
laboratory with the use of the Dako PD-L1 IHC 
28-8 pharmDx test, and health-related quality of 
life on the basis of the score on the National 
Comprehensive Cancer Network Functional As-
sessment of Cancer Therapy–Kidney Symptom 
Index (FKSI-19) (see the Supplementary Appendix), 
both in intermediate- and poor-risk patients.17,18 
FKSI-19 scores range from 0 to 76, with higher 
scores indicating fewer symptoms.
Disease assessments were performed with com-
puted tomography or magnetic resonance imaging 
at baseline, 12 weeks after randomization, con-
tinuing every 6 weeks for the first 13 months, 
and then every 12 weeks until progression or 
treatment discontinuation. After progression or 
treatment discontinuation, patients were followed 
for safety and survival. Adverse events were 
graded according to the National Cancer Institute 
Common Terminology Criteria for Adverse Events, 
version 4.0.19 Patients in both groups were al-
lowed to continue therapy after initial investiga-
tor-assessed, RECIST-defined progression if they 
had clinical benefit without disabling toxic ef-
fects. Patients discontinued trial therapy on evi-
dence of further progression, defined as an ad-
ditional 10% or greater increase in tumor burden 
volume from the time of initial progression (in-
cluding all target lesions and new measurable 
lesions) according to investigator assessment.
Statistical Analysis
It was estimated that 1070 patients would under-
go randomization, with 820 having IMDC inter-
mediate or poor risk (the proportion expected 
according to the distribution in the general popu-
lation and the number needed for robust statisti-
cal analyses). Enrollment was discontinued once 
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approximately 820 patients (77%) with IMDC in-
termediate or poor risk had undergone random-
ization.
The overall alpha level was 0.05, split among 
three coprimary end points. The objective re-
sponse rate was analyzed at an alpha level of 
0.001. Progression-free survival was evaluated at 
an alpha level of 0.009, with a power of 80% or 
more. We evaluated overall survival at an alpha 
level of 0.04 with 90% power (independent of 
coprimary end points) on the basis of a hazard 
ratio of 0.77, accounting for two formal interim 
analyses after 51% (reported herein) and 75% of 
deaths had occurred, using a stratified log-rank 
test. An O’Brien and Fleming alpha spending 
function was used to determine nominal sig-
nificance levels that were based on the number 
of deaths for the interim and final analyses and 
stopping boundaries, and an adjusted alpha level 
of 0.002 was used for the first interim analysis. 
The critical hazard ratio for the first interim 
analysis of overall survival was 0.72. The strati-
fied hazard ratio between treatment groups is 
presented along with the 99.8% confidence in-
terval (adjusted for interim analyses). For progres-
sion-free survival, a two-sided stratified 99.1% 
confidence interval for the hazard ratio was cal-
culated. Confidence intervals were defined on 
the basis of the respective alpha allocated to that 
end point. Estimates of response rate, along with 
the exact two-sided 95% confidence interval by 
the Clopper–Pearson method,20 were computed. 
Overall survival, progression-free survival, and 
duration of response were estimated with the 
use of Kaplan–Meier methods.
For quality-of-life assessments, descriptive sta-
tistics and change from baseline were conducted 
for the FKSI-19 score. Calculations of P values, to 
evaluate the between-group difference in mean 
change from baseline, were based on an indepen-
dent-samples t-test under the assumption that 
variances were unequal. Both a pattern-mixture 
model and a restricted maximum likelihood–based 
repeated-measures approach were used to confirm 
descriptive data.
R esult s
Patients
From October 2014 through February 2016, a 
total of 1096 patients were randomly assigned to 
treatment at 175 sites in 28 countries; 1082 pa-
tients received treatment (547 with nivolumab 
plus ipilimumab and 535 with sunitinib in the in-
tention-to-treat population; 423 and 416, respec-
tively, had intermediate or poor risk). At the time 
of the database lock (August 7, 2017), 128 of 547 
patients (23%) in the nivolumab-plus-ipilimu-
mab group and 97 of 535 (18%) in the sunitinib 
group continued treatment (Fig. S1 in the Sup-
plementary Appendix). The primary reason for 
treatment discontinuation was disease progres-
sion, observed in 229 of 547 patients (42%) in 
the nivolumab-plus-ipilimumab group and 296 
of 535 (55%) in the sunitinib group (Fig. S1 in 
the Supplementary Appendix). Patient character-
istics were similar in the two treatment groups, 
and the characteristics of the intermediate- and 
poor-risk patients were similar to those of the 
intention-to-treat population (Table 1). The me-
dian follow-up was 25.2 months; the minimum 
follow-up was 17.5 months.
Efficacy
Coprimary End Points in Intermediate-  
and Poor-Risk Patients
Nivolumab plus ipilimumab had a significant over-
all survival benefit over sunitinib; the 12-month 
overall survival rate was 80% (95% confidence 
interval [CI], 76 to 84) with nivolumab plus ipi-
limumab versus 72% (95% CI, 67 to 76) with 
sunitinib, and the 18-month overall survival rate 
was 75% (95% CI, 70 to 78) versus 60% (95% CI, 
55 to 65) (hazard ratio for death, 0.63; 99.8% CI, 
0.44 to 0.89; P<0.001). The median overall sur-
vival was not reached (95% CI, 28.2 months to 
not estimable) with nivolumab plus ipilimumab 
versus 26.0 months (95% CI, 22.1 to not esti-
mable) with sunitinib (Fig. 1A).
The coprimary end point of objective re-
sponse rate was 42% (95% CI, 37 to 47) with 
nivolumab plus ipilimumab versus 27% (95% CI, 
22 to 31) with sunitinib (P<0.001), with complete 
responses in 40 patients (9%) versus 5 patients 
(1%) (Table 2). Of all intermediate- and poor-risk 
patients, 81% of those treated with nivolumab 
plus ipilimumab and 70% of those treated with 
sunitinib had a duration of response of at least 
1 year, and the median duration of response was 
not reached (95% CI, 21.8 months to not estima-
ble) and 18.2 months (95% CI, 14.8 to not esti-
mable), respectively (Table 2, and Fig. S2 in the 
Supplementary Appendix). Rates of investigator-
assessed objective response were consistent with 
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rates of independently assessed objective response 
(Table S1 in the Supplementary Appendix).
For the coprimary end point of progression-free 
survival, the median was 11.6 months (95% CI, 8.7 
to 15.5) with nivolumab plus ipilimumab and 8.4 
months (95% CI, 7.0 to 10.8) with sunitinib (Fig. 
1B). The between-group difference did not meet the 
prespecified threshold (P = 0.009) for statistical sig-
nificance (hazard ratio for disease progression or 
death, 0.82; 99.1% CI, 0.64 to 1.05; P = 0.03).
Characteristic IMDC Intermediate- and Poor-Risk Patients Intention-to-Treat Population
Nivolumab plus 
Ipilimumab 
(N = 425)
Sunitinib 
(N = 422)
Nivolumab plus 
Ipilimumab 
(N = 550)
Sunitinib 
(N = 546)
Median age (range) — yr 62 (26–85) 61 (21–85) 62 (26–85) 62 (21–85)
Sex — no. (%)
Male 314 (74) 301 (71) 413 (75) 395 (72)
Female 111 (26) 121 (29) 137 (25) 151 (28)
IMDC prognostic risk — no. (%)†
Favorable 0 0 125 (23) 124 (23)
Intermediate 334 (79) 333 (79) 334 (61) 333 (61)
Poor 91 (21) 89 (21) 91 (17) 89 (16)
Geographic region — no. (%)
United States 112 (26) 111 (26) 154 (28) 153 (28)
Canada and Europe 148 (35) 146 (35) 201 (37) 199 (36)
Rest of the world 165 (39) 165 (39) 195 (35) 194 (36)
Quantifiable tumor PD-L1 expression — no./
total no. with evaluable data (%)
<1% 284/384 (74) 278/392 (71) 386/499 (77) 376/503 (75)
≥1% 100/384 (26) 114/392 (29) 113/499 (23) 127/503 (25)
Previous radiotherapy — no. (%) 52 (12) 52 (12) 63 (11) 70 (13)
Previous nephrectomy — no. (%) 341 (80) 319 (76) 453 (82) 437 (80)
No. of sites with target or nontarget lesions 
— no. (%)‡
1 90 (21) 84 (20) 123 (22) 118 (22)
≥2 335 (79) 337 (80) 427 (78) 427 (78)
Most common sites of metastasis — no. (%)
Lung 294 (69) 296 (70) 381 (69) 373 (68)
Lymph node 190 (45) 216 (51) 246 (45) 268 (49)
Bone§ 95 (22) 97 (23) 112 (20) 119 (22)
Liver 88 (21) 89 (21) 99 (18) 107 (20)
*  Information shown in the table is based on data collected with the use of an interactive voice-response system. Percentages may not total
100 because of rounding. IMDC denotes International Metastatic Renal Cell Carcinoma Database Consortium, and PD-L1 programmed
death ligand 1.
†  Patients with favorable risk had an IMDC score of 0, those with intermediate risk had a score of 1 or 2, and those with poor risk had a score 
of 3 to 6. IMDC risk scores are defined by the number of the following risk factors present: a Karnofsky performance-status score of 70 (on a
scale from 0 to 100, with lower scores indicating greater disability; patients with a performance-status score of <70 were excluded from the
trial), a time from initial diagnosis to randomization of less than 1 year, a hemoglobin level below the lower limit of the normal range, a cor-
rected serum calcium concentration of more than 10 mg per deciliter (2.5 mmol per liter), an absolute neutrophil count above the upper
limit of the normal range, and a platelet count above the upper limit of the normal range.
‡  The number of target or nontarget lesions at baseline was not reported for one patient in the sunitinib group.
§  Shown are patients who had bone metastases with or without a soft-tissue component.
Table 1. Baseline Demographic and Clinical Characteristics of the Patients Who Underwent Randomization.*
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Overall survival favored nivolumab plus ipi lim-
umab over sunitinib across subgroups (Fig. 2). 
Similarly, the objective response rate was higher 
with nivolumab plus ipilimumab than with suni-
tinib in all subgroups (Fig. S3 in the Supplemen-
tary Appendix).
Secondary End Points in the Intention-to-Treat 
Population
In the intention-to-treat population (patients with 
favorable, intermediate, or poor risk), the 12-month 
overall survival rate was 83% (95% CI, 80 to 86) 
with nivolumab plus ipilimumab versus 77% 
Figure 1. Overall Survival and Progression-free Survival among IMDC Intermediate- and Poor-Risk Patients.
Progression was defined according to the Response Evaluation Criteria in Solid Tumors, version 1.1. For progres-
sion-free survival, the between-group difference did not meet the prespecified threshold (P = 0.009) for statistical 
significance. IMDC denotes International Metastatic Renal Cell Carcinoma Database Consortium, NE not estimable, 
and NR not reached.
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(95% CI, 74 to 81) with sunitinib, and the 18-month 
overall survival rate was 78% (95% CI, 74 to 81) 
versus 68% (95% CI, 63 to 72). The median over-
all survival was not reached versus 32.9 months. 
Nivolumab plus ipilimumab had a significant over-
all survival benefit over sunitinib (hazard ratio 
for death, 0.68; 99.8% CI, 0.49 to 0.95; P<0.001). 
The rate of independently assessed objective re-
sponse was 39% (95% CI, 35 to 43) with nivolu-
mab plus ipilimumab and 32% (95% CI, 28 to 
36) with sunitinib (P = 0.02, not significant per
the prespecified 0.001 threshold). The median 
progression-free survival was 12.4 months (95% 
CI, 9.9 to 16.5) with nivolumab plus ipilimumab 
and 12.3 months (95% CI, 9.8 to 15.2) with suni-
tinib. Progression-free survival did not differ 
significantly between the two groups (hazard 
ratio for disease progression or death, 0.98; 
99.1% CI, 0.79 to 1.23; P = 0.85).
Exploratory Analyses of Favorable-Risk Patients
The baseline characteristics of the 249 favorable-
risk patients were similar to those of the inter-
mediate- and poor-risk patients and of the inten-
tion-to-treat population, except that the baseline 
PD-L1 expression level was lower in favorable-risk 
patients (Table S2 in the Supplementary Appen-
dix). The 12-month overall survival rate was 94% 
(95% CI, 87 to 97) with nivolumab plus ipilim-
umab and 96% (95% CI, 90 to 98) with suni-
tinib, and the 18-month overall survival rate was 
88% (95% CI, 80 to 92) and 93% (95% CI, 87 to 
97), respectively (the hazard ratio for death favored 
sunitinib: 1.45; 99.8% CI, 0.51 to 4.12; P = 0.27). 
However, only 37 deaths had occurred at the 
time of the database lock (21 in the nivolumab-
plus-ipilimumab group and 16 in the sunitinib 
group); the median overall survival was not reached 
and 32.9 months (95% CI, not estimable), respec-
tively. The objective response rate was 29% (95% 
CI, 21 to 38) with nivolumab plus ipilimumab 
versus 52% (95% CI, 43 to 61) with sunitinib 
(P<0.001), and the median progression-free sur-
vival was 15.3 months (95% CI, 9.7 to 20.3) ver-
sus 25.1 months (95% CI, 20.9 to not estimable) 
(hazard ratio for disease progression or death, 
2.18; 99.1% CI, 1.29 to 3.68; P<0.001), both fa-
voring sunitinib. However, the rate of complete 
response was 11% with nivolumab plus ipilim-
umab and 6% with sunitinib.
Exploratory Outcomes According to PD-L1 
Expression Level
Among 776 intermediate- and poor-risk patients 
who had quantifiable PD-L1 expression, 100 of 
384 patients (26%) in the nivolumab-plus-ipilim-
umab group and 114 of 392 patients (29%) in the 
sunitinib group had 1% or greater PD-L1 expres-
sion. In exploratory analyses, overall survival 
among the 776 patients was longer with nivolu-
Variable
Nivolumab plus Ipilimumab 
(N = 425)
Sunitinib 
(N = 422)
Confirmed objective response rate — % (95% CI)† 42 (37–47)‡ 27 (22–31)‡
Confirmed best overall response — no. (%)†
Complete response 40 (9)‡§ 5 (1)‡§
Partial response 137 (32) 107 (25)
Stable disease 133 (31) 188 (45)
Progressive disease 83 (20) 72 (17)
Unable to determine or not reported 32 (8) 50 (12)
Median time to response (range) — mo 2.8 (0.9–11.3) 3.0 (0.6–15.0)
Median duration of response (95% CI) — mo NR (21.8–NE) 18.2 (14.8–NE)
Patients with ongoing response — no./total no. (%) 128/177 (72) 71/112 (63)
*  NE denotes not estimable, and NR not reached.
†  Response was assessed according to Response Evaluation Criteria in Solid Tumors, version 1.1, by an independent 
 radiology review committee.
‡  P<0.001 for the difference between groups.
§  The analysis of the between-group difference in complete response was exploratory.
Table 2. Antitumor Activity in IMDC Intermediate- and Poor-Risk Patients.*
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mab plus ipilimumab than with sunitinib across 
PD-L1 expression levels (Fig. S4 in the Supplemen-
tary Appendix). The 12-month overall survival rate 
with less than 1% PD-L1 expression was 80% 
(95% CI, 75 to 84) with nivolumab plus ipilim-
umab and 75% (95% CI, 70 to 80) with suni-
tinib, and the 18-month overall survival rate was 
74% (95% CI, 69 to 79) and 64% (95% CI, 58 to 70), 
respectively; the median overall survival was not 
reached in both groups (hazard ratio for death, 
0.73; 95% CI, 0.56 to 0.96). In patients with 1% or 
greater PD-L1 expression, the 12-month overall 
Figure 2. Subgroup Analysis of Overall Survival among IMDC Intermediate- and Poor-Risk Patients.
Patients with intermediate risk had an IMDC score of 1 or 2, and those with poor risk had a score of 3 to 6. IMDC 
risk scores are defined by the number of the following risk factors present: a Karnofsky performance-status score  
of 70 (on a scale from 0 to 100, with lower scores indicating greater disability; patients with a performance-status 
score of <70 were excluded from the trial), a time from initial diagnosis to randomization of less than 1 year, a he-
moglobin level below the lower limit of the normal range, a corrected serum calcium concentration of more than  
10 mg per deciliter (2.5 mmol per liter), an absolute neutrophil count above the upper limit of the normal range, 
and a platelet count above the upper limit of the normal range. Bone, liver, lung, and lymph-node metastases were 
not protocol-prespecified subgroups. PD-L1 denotes programmed death ligand 1.
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survival rate was 86% (95% CI, 77 to 91) with 
nivolumab plus ipilimumab and 66% (95% CI, 
56 to 74) with sunitinib, and the 18-month over-
all survival rate was 81% (95% CI, 71 to 87) and 
53% (95% CI, 43 to 62), respectively; the median 
overall survival was not reached and 19.6 months 
(95% CI, 14.8 to not estimable), respectively 
(hazard ratio for death, 0.45; 95% CI, 0.29 to 
0.71) (Fig. S4 in the Supplementary Appendix).
The objective response rate among patients 
with less than 1% PD-L1 expression was 37% 
with nivolumab plus ipilimumab and 28% with 
sunitinib (P = 0.03); among patients with 1% or 
greater PD-L1 expression, the objective response 
rate was 58% versus 22% (P<0.001) (Table S3 in 
the Supplementary Appendix). The median pro-
gression-free survival among patients with less 
than 1% PD-L1 expression was 11.0 months with 
nivolumab plus ipilimumab and 10.4 months 
with sunitinib (hazard ratio for disease progres-
sion or death, 1.00; 95% CI, 0.80 to 1.26); among 
patients with 1% or greater PD-L1 expression, the 
median progression-free survival was 22.8 and 
5.9 months, respectively (hazard ratio for disease 
progression or death, 0.46; 95% CI, 0.31 to 0.67). 
A similar trend was observed among patients with 
5% or greater PD-L1 expression, as compared with 
patients with less than 5% PD-L1 expression (not 
shown).
Exposure and Safety
The median duration of treatment in all patients 
who received a trial drug was 7.9 months (95% CI, 
6.5 to 8.4) with nivolumab plus ipilimumab and 
7.8 months (95% CI, 6.4 to 8.5) with sunitinib. 
A total of 79% of the patients received all four 
doses of ipilimumab with nivolumab. Among 
the 547 patients treated with nivolumab plus 
ipilimumab, nivolumab dose delays occurred in 
319 (58%), and ipilimumab dose delays occurred 
in 148 (27%). Among the 535 patients treated with 
sunitinib, dose delays occurred in 315 (59%), and 
dose reductions occurred in 283 (53%). A total 
of 157 of 550 patients (29%) in the nivolumab-
plus-ipilimumab group and 129 of 546 patients 
(24%) in the sunitinib group were treated beyond 
initial investigator-assessed, RECIST-defined pro-
gression, as permitted according to the protocol.
Treatment-related adverse events of any grade 
occurred in 509 of 547 patients (93%) treated 
with nivolumab plus ipilimumab and 521 of 535 
patients (97%) treated with sunitinib (Table 3). 
Grade 3 or 4 events occurred in 250 patients 
(46%) and 335 patients (63%) in the respective 
groups. Treatment-related adverse events leading 
to discontinuation occurred in 118 of 547 pa-
tients (22%) in the nivolumab-plus-ipilimumab 
group and 63 of 535 patients (12%) in the suni-
tinib group. Eight deaths in the nivolumab-plus-
ipilimumab group and four deaths in the suni-
tinib group were reported to be treatment-related 
(Table 3). Of the 436 patients treated with nivolu-
mab plus ipilimumab who had a treatment-related 
select (immune-mediated) adverse event (includes 
skin, endocrine, gastrointestinal, pulmonary, he-
patic, and renal categories), 152 (35%) received 
high-dose glucocorticoids (≥40 mg of prednisone 
per day or equivalent).
Quality of Life
The rate of completion of the FKSI-19 question-
naire exceeded 80% in both groups during the 
first 6 months. The mean baseline FKSI-19 score 
(a quality-of-life metric) was similar in the two 
groups among patients with intermediate or poor 
risk (60.1 for nivolumab plus ipilimumab and 
59.1 for sunitinib); the mean change from base-
line was greater in the nivolumab-plus-ipilim-
umab group than in the sunitinib group at each 
assessment during the first 6 months (P<0.001) 
(Fig. 3). The pattern-mixture model and the mixed-
model repeated-measures approach indicated a 
significant difference in favor of nivolumab plus 
ipilimumab, which substantiated the descriptive 
results (not shown).
Subsequent Therapy
Among randomly assigned patients, 217 of 550 
(39%) in the nivolumab-plus-ipilimumab group 
and 295 of 546 (54%) in the sunitinib group re-
ceived subsequent systemic therapy. The most 
common subsequent therapies were sunitinib 
(111 patients, 20%) and pazopanib (72 patients, 
13%) in the nivolumab-plus-ipilimumab group 
and nivolumab (147 patients, 27%) and axitinib 
(106 patients, 19%) in the sunitinib group.
Discussion
In this randomized, phase 3 trial involving pre-
viously untreated patients with advanced renal-
cell carcinoma, two of the three coprimary end 
points were met; among intermediate- and poor-
risk patients, the risk of death was 37% lower 
n engl j med 378;14 nejm.org April 5, 20181286
Th e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
with nivolumab plus ipilimumab than with suni-
tinib, and the objective response rate was higher 
with nivolumab plus ipilimumab (42% vs. 27%). 
The 9% complete response rate with nivolumab 
plus ipilimumab compared favorably with the 
1% observed with sunitinib and with a complete 
response rate of 1% or less reported with other 
tyrosine kinase inhibitor therapies.2,21 A signifi-
cant difference in overall survival favoring nivolu-
mab plus ipilimumab was also observed in the 
intention-to-treat population (18-month overall 
survival rate, 78% [95% CI, 74 to 81] with nivolu-
mab plus ipilimumab vs. 68% with sunitinib 
[95% CI, 63 to 72]; hazard ratio for death, 0.68; 
99.8% CI, 0.49 to 0.95; P<0.001).
Progression-free survival among intermediate- 
and poor-risk patients was longer with nivolu-
mab plus ipilimumab than with sunitinib but 
did not meet the prespecified boundary for sta-
tistical significance (alpha level, 0.009), partly 
owing to the distribution of the alpha level 
across three coprimary end points. The curves 
separated at 6 months after randomization and 
followed a pattern similar to that observed in a 
randomized, phase 3 trial comparing nivolumab 
with everolimus in previously treated advanced 
renal-cell carcinoma.22
Longer progression-free survival with nivolu-
mab plus ipilimumab than with sunitinib was ob-
served among patients with 1% or greater PD-L1 
Event
Nivolumab plus Ipilimumab 
(N = 547)
Sunitinib 
(N = 535)
Any Grade† Grade 3 or 4 Any Grade‡ Grade 3 or 4
number of patients (percent)
All events 509 (93) 250 (46) 521 (97) 335 (63)
Fatigue 202 (37) 23 (4) 264 (49) 49 (9)
Pruritus 154 (28) 3 (<1) 49 (9) 0
Diarrhea 145 (27) 21 (4) 278 (52) 28 (5)
Rash 118 (22) 8 (1) 67 (13) 0
Nausea 109 (20) 8 (1) 202 (38) 6 (1)
Increased lipase level 90 (16) 56 (10) 58 (11) 35 (7)
Hypothyroidism 85 (16) 2 (<1) 134 (25) 1 (<1)
Decreased appetite 75 (14) 7 (1) 133 (25) 5 (<1)
Asthenia 72 (13) 8 (1) 91 (17) 12 (2)
Vomiting 59 (11) 4 (<1) 110 (21) 10 (2)
Anemia 34 (6) 2 (<1) 83 (16) 24 (4)
Dysgeusia 31 (6) 0 179 (33) 1 (<1)
Stomatitis 23 (4) 0 149 (28) 14 (3)
Dyspepsia 15 (3) 0 96 (18) 0
Mucosal inflammation 13 (2) 0 152 (28) 14 (3)
Hypertension 12 (2) 4 (<1) 216 (40) 85 (16)
Palmar–plantar erythrodysesthesia 5 (<1) 0 231 (43) 49 (9)
Thrombocytopenia 2 (<1) 0 95 (18) 25 (5)
*  These events were considered by investigators to be related to treatment.
†  There were eight treatment-related deaths in the nivolumab-plus-ipilimumab group: one each due to pneumonitis, pneu-
monia and aplastic anemia (the cause of death in this case was updated after the database lock to treatment-related),
immune-mediated bronchitis, lower gastrointestinal hemorrhage, the hemophagocytic syndrome, sudden death, liver
toxic effects, and lung infection.
‡  There were four treatment-related deaths in the sunitinib group: two due to cardiac arrest and one each due to heart 
failure and multiple organ failure.
Table 3. Treatment-Related Adverse Events Occurring in 15% or More of Treated Patients in Either Group.*
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expression but not among those with less than 
1% PD-L1 expression. In contrast, longer overall 
survival and a higher objective response rate were 
observed with nivolumab plus ipilimumab than 
with sunitinib among intermediate- and poor-risk 
patients across tumor PD-L1 expression levels, 
although the magnitude of benefit was higher in 
the population with 1% or greater PD-L1 expres-
sion. This suggests that PD-L1 expression is not 
entirely predictive of response to and overall sur-
vival benefit from the combination, as was also 
the case with nivolumab monotherapy as second-
line treatment, in which a survival benefit was 
observed across PD-L1 expression levels, and in 
contrast to published data for sunitinib that 
showed better outcomes in patients with lower 
PD-L1 expression levels.22,23
Three quarters of the patients with advanced 
renal-cell carcinoma have intermediate- or poor-
risk clinical features.4 In this trial, 23% of the 
patients had favorable prognostic risk. The favor-
able-risk group had a higher objective response 
rate and longer progression-free survival with 
sunitinib than with nivolumab plus ipilimumab; 
these differences did not translate into a signifi-
cant survival advantage. These results in favorable-
risk patients should be interpreted with caution 
because of the exploratory nature of the analysis, 
the small subgroup sample, and the immaturity 
of survival data. However, they highlight the need 
to better understand the underlying biologic pro-
cesses driving responses to these two different 
treatment regimens.
The safety profile of nivolumab plus ipilim-
umab was consistent with that in previous stud-
ies in multiple tumor types, including advanced 
renal-cell carcinoma,10-12,14,24 with a lower inci-
dence of grade 3 and 4 treatment-related adverse 
events than observed with sunitinib. The frequen-
cies of treatment-related gastrointestinal, skin, 
and hepatic adverse events were lower than those 
seen in a trial involving patients with melanoma, 
in which a higher dose of ipilimumab (3 mg per 
kilogram) and a lower dose of nivolumab (1 mg 
per kilogram) were used.13 Dose delays, treatment 
with glucocorticoids, and prompt diagnostic work-
up to rule out noninflammatory causes were used 
to manage toxic effects according to management 
Figure 3. Health-Related Quality of Life in IMDC Intermediate- and Poor-Risk Patients.
Scores on the National Comprehensive Cancer Network Functional Assessment of Cancer Therapy–Kidney Symptom 
Index (FKSI-19) range from 0 to 76, with higher scores indicating fewer symptoms. Only time points for which data 
were available for five or more patients are shown. The number at risk shows the number of randomly assigned pa-
tients who were in the trial at each respective time point. I bars indicate standard errors.
M
ea
n 
C
ha
ng
e 
fr
om
 B
as
el
in
e 
FK
SI
-1
9 
Sc
or
e
10
6
8
4
2
−2
−4
−8
0
7
9
5
3
1
−6
−3
−5
−9
−1
−7
−10
0 16 32 40 60 76 104
Week
No. at Risk
Nivolumab+ipilimumab
Sunitinib
425
422
281
284
8
347
371
212
184
24
239
221
180
147
152
113
52
166
127
139
93
76
43
68
143
104
84
125
80
88 92
108
64
96 10012 28 36 56 724 20 4844 64 80
44
26
Nivolumab+ipilimumab
Sunitinib
n engl j med 378;14 nejm.org April 5, 20181288
Th e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
algorithms developed for immuno-oncology treat-
ment-related adverse events.25 Patients reported 
better health-related quality of life, as measured 
by the FKSI-19, with nivolumab plus ipilimumab 
than with sunitinib.
The approved standard dose of sunitinib was 
used in this trial, and the data compare favorably 
with those in previous phase 3 trials of sunitinib.2 
Alternate sunitinib schedules, such as 2 weeks on 
followed by 1 week off, may influence efficacy 
outcomes, the adverse-event profile, and adher-
ence to therapy, although data from randomized 
trials are lacking.26
Progress in first-line treatment of renal-cell 
carcinoma has led to regulatory approval of three 
antiangiogenic drugs and one mammalian target 
of rapamycin inhibitor, although approval was 
largely due to a benefit with respect to progres-
sion-free survival rather than overall survival.27-31 
Few studies thus far have been conducted to spe-
cifically address the efficacy of these drugs as 
first-line therapy in intermediate- and poor-risk 
patients.4,32
This trial showed an efficacy and overall sur-
vival benefit of nivolumab plus ipilimumab over 
sunitinib in the first-line treatment of interme-
diate- or poor-risk advanced clear-cell renal-cell 
carcinoma.
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